Normal view MARC view ISBD view

Evaluation and management of skeletal disease in cancer care. [Review]

MedStar author(s):

Citation: Critical Reviews in Oncology-Hematology. 120:217-226, 2017 DecPMID: 29032892Institution: MedStar Washington Hospital CenterDepartment: Medicine/Internal MedcineForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Bone Diseases/pp [Physiopathology] | *Bone Diseases/th [Therapy] | *Neoplasms/pp [Physiopathology] | *Neoplasms/th [Therapy] | Bone Diseases/di [Diagnosis] | Bone Neoplasms/pp [Physiopathology] | Bone Neoplasms/sc [Secondary] | Cancer Survivors | Humans | Neoplasms/pa [Pathology]Year: 2017 ISSN:

1040-8428

Name of journal: Critical reviews in oncology/hematologyAbstract: Copyright Published by Elsevier B.V.Recently, there have been considerable advancements in cancer therapies thereby prolonging the life of cancer survivors. However, these recent advancements present new challenges in the management of bone disease in cancer survivors. Bone acts as a fertile soil for cancer seeding and bone health is often compromised because of increased inflammatory cytokines in cancer, direct cancer metastasis and toxic effects of anti-cancer therapies. This effect is more pronounced in elderly population who already have compromised bone mineral density leading to increased skeletal related events and bone pain. Timely diagnosis and effective interventions are essential for reducing bone-related morbidity in cancer survivors. Also, a complex interdependence exists between cancer related bone disease and tumor growth, creating a vicious circle of extensive bone destruction and cancer progression. Hence, maintenance of bone health and integrity plays a pivotal role in comprehensive cancer care. The bone-targeted treatments have been shown to preserve bone health, and modify the course of the underlying cancer. Management of long-term bone health requires a broad knowledge base that endocrinologists, oncologists and other care team members should be aware of. The manuscript highlights the skeletal effects of cancer, adjuvant therapies used for hormone-responsive cancers, chemotherapy induced bone loss and steps for accurate diagnosis and management of bone disease in cancer survivors by bridging the gaps in the comprehensive cancer care.All authors: Correa R, Esquivel MA, Kommalapati A, Tella SHFiscal year: FY2018Digital Object Identifier:

https://dx.doi.org/10.1016/j.critrevonc.2017.09.003

Date added to catalog: 2017-11-10

Holdings ( 1 )
Title notes ( 3 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	29032892	Available		29032892

Recently, there have been considerable advancements in cancer therapies thereby prolonging the life of cancer survivors. However, these recent advancements present new challenges in the management of bone disease in cancer survivors. Bone acts as a fertile soil for cancer seeding and bone health is often compromised because of increased inflammatory cytokines in cancer, direct cancer metastasis and toxic effects of anti-cancer therapies. This effect is more pronounced in elderly population who already have compromised bone mineral density leading to increased skeletal related events and bone pain. Timely diagnosis and effective interventions are essential for reducing bone-related morbidity in cancer survivors. Also, a complex interdependence exists between cancer related bone disease and tumor growth, creating a vicious circle of extensive bone destruction and cancer progression. Hence, maintenance of bone health and integrity plays a pivotal role in comprehensive cancer care. The bone-targeted treatments have been shown to preserve bone health, and modify the course of the underlying cancer. Management of long-term bone health requires a broad knowledge base that endocrinologists, oncologists and other care team members should be aware of. The manuscript highlights the skeletal effects of cancer, adjuvant therapies used for hormone-responsive cancers, chemotherapy induced bone loss and steps for accurate diagnosis and management of bone disease in cancer survivors by bridging the gaps in the comprehensive cancer care.

English